Corporate Presentation - Delivering on our commitment to patients - Zealand pharma

Page created by Craig Flores
 
CONTINUE READING
Corporate Presentation - Delivering on our commitment to patients - Zealand pharma
Corporate
PresentationŸ
Delivering on our commitment to patients

                                           April 2021
Corporate Presentation - Delivering on our commitment to patients - Zealand pharma
Contents

Introduction: Zealand Today and
2025 Ambition

Commercial Programs

Clinical Programs

Pre-Clinical Pipeline

Additional Company Information

Corporate Presentation            2
Corporate Presentation - Delivering on our commitment to patients - Zealand pharma
Forward looking statement

This presentation contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, that
provide Zealand Pharma’s expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical
products.

The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and
inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-
looking statements to be incorrect, and which include, but are not limited to, the occurrence of adverse safety events; risks of unexpected costs or
delays; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; failure to protect and enforce our data,
intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may
require additional information or further studies, or may fail to approve or may delay approval of our drug candidates or expansion of product labeling;
failure to obtain regulatory approvals in other jurisdictions; product liability claims; and the direct and indirect impacts of the ongoing COVID-19 pandemic
on our business, results of operations and financial condition.

If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or
implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any
forward-looking statement.

All such forward-looking statements speak only as of the date of this presentation and are based on information available to Zealand Pharma as of the
date of this release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date
hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising
or medical advice.

Corporate Presentation                                                                                                                                           3
Corporate Presentation - Delivering on our commitment to patients - Zealand pharma
Zealand Today and
2025 ambition•
Corporate Presentation Ÿ   4
Corporate Presentation - Delivering on our commitment to patients - Zealand pharma
Zealand Pharma is entering an exciting 2021

                         Plan for a successful launch of Zegalogue® and optimize
                         commercialization

                            Execute on our robust late-stage clinical pipeline

                                 Advance our early-stage programs into the clinic

                                       Maintain a strong financial and
                                       organizational position

Corporate Presentation                                                              5
Corporate Presentation - Delivering on our commitment to patients - Zealand pharma
We are boldly pursuing our ambition as a fully
integrated biotech
                                              Invest in innovative peptide research platform

5x25
                                              and robust pipeline

 Have 5 commercialized products by 2025

 Optimize commercial operations               Maintaining a strong balance sheet1
                                              DKK thousand

  Fully operational US                        1,500,000
  infrastructure
                                              1,000,000
  High prescriber coverage
  Established relationships                     500,000
  with KOLs and HCPs
                                                        0
                                                                2016           2017          2018           2019           2020
                                                        Cash & cash equivalents            Restricted cash         Securities

Corporate Presentation
                                          1                                                                                              6
                                              Additional DKK 749 million gross proceeds secured through directed issue in January 2021
Corporate Presentation - Delivering on our commitment to patients - Zealand pharma
Significant pipeline evolution and a commitment to
    continue to deliver        Preclinical Phase 1 Phase 2 Phase 3
                                                                   Approved/
                                                                                                                                                                 Cleared
           Metabolic

                                V-Go® Wearable Insulin Delivery                     Type 2 Diabetes management

                                ZEGALOGUE® (dasiglucagon) injection                 Severe hypoglycemia in diabetes

                                Dasiglucagon S.C. Continuous Infusion               Congenital hyperinsulinism

                                Dasiglucagon Bi-Hormonal Artificial Pancreas Pump   Type 1 Diabetes management
           Metabolic

                                Dasiglucagon Adjustable Mini-Dose                   PBH/ T1D exercise-induced hypo

                                BI 456906 GLP-1/GLU Dual Agonist1                   Obesity/ NASH/ T2D

                                ZP 8396 Amylin Analog                               Obesity

                                ZP 6590 GIP Agonist                                 Obesity

                                Glepaglutide GLP-2 Analog                           Short Bowel Syndrome
            GI & Inflammatory

                                Dapiglutide GLP-1/GLP-2 Dual Agonist                SBS+

                                ZP 9830 Kv1.3 Ion Channel Blocker                   IBD+
                                ZP 10000 ɑ4β7 Integrin Inhibitor                    IBD

                                Complement C3 Inhibitor2                            Undisclosed

1   Licensed to Boehringer Ingelheim: EUR 345 million outstanding potential development, regulatory and commercial milestones + high single to low double digit % royalties on global sales
2   Licensed to Alexion: USD 610 million potential development, regulatory and commercial milestones + high single to low double digits % royalties on net sales
Corporate Presentation                                                                                                                                                                        7
Corporate Presentation - Delivering on our commitment to patients - Zealand pharma
Commercial
programs•
Corporate Presentation   8
Corporate Presentation - Delivering on our commitment to patients - Zealand pharma
Commercial Overview

                         Severe         Type 2
                         hypoglycemia   Diabetes

Corporate Presentation                             9
Corporate Presentation - Delivering on our commitment to patients - Zealand pharma
Severe
                 hypoglycemia
                                                    “Diabetes affects me all the time,
             Severe hypoglycemia is an acute,
    life-threatening condition resulting from a         and I have to think about
 critical drop in blood glucose levels. Among            it no matter what I do.”
  the most feared complications of diabetes
                                                       Anders, living with Type 1 diabetes
    treatment, severe hypoglycemia requires
                     another person for rescue

                    Read more of Anders’ story at
               zealandpharma.com/anders-story

Corporate Presentation                                                                       10
Severe hypoglycemia remains a
    major issue for people on insulin
    • Insulin treatment is the main cause of
      severe hypoglycemia in people with diabetes1
    • 8.4M Adults and Children on Insulin Therapy2
           • Approximately 4.0M patients are on Multiple
             Daily Injections of Insulin3
    • Despite this, there were only approximately 540,000
      patients with glucagon therapy in 20204
    • Glucagon should be prescribed for all individuals at
      increased risk of level 2 or 3 hypoglycemia so that it
      is available should it be needed5

1The International Hypoglycemia Study Group. Lancet Diab and Endo 2019; 7,(5): 385-96.; 2 Diabetes Surveillance System,
Centers for Disease Control: gis.cdc.gov/grasp/diabetes/diabetesatlas.html; Accessed March 1, 2021. 3 Brixner et
al. ClinTher. 2019 Feb;41(2):303-313. 4 Symphony Health Trx Quantity; 5 ADA Standards of care. Diabetes Care 2021 Jan; 44
(Supplement 1): S1-S2
Corporate Presentation                                                                                                      11
ZEGALOGUE provides an attractive treatment option for
patients and providers alike

                                                                         Recovery

                                                   Consistent        99% of patients in the main adult phase
                                                                     3 trial recovered within 15 minutes

                                10
                              minutes           All pivotal phase 3 studies
                                                reported the same median time to recovery

                          Median time to blood glucose recovery
                          of 10 minutes in adults and children

 Corporate Presentation
                                                                                                        12
ZEGALOGUE will launch at the right time in a growing
market that is driven by innovation
           Launch timed to capture                       Rescue market growing with                      Innovation driven market with
         ‘Back to school’ seasonality                           new entrants                             new entrants capturing share

                                                         TRx Units Dispensed (M)

                                                         1.2

                                   +60% Rx Volume Lift                                    +10%

                                                                            +6%
  Weekly Glucagon Market

                                                         0.9                                     ~300m
                                                                                                  USD                                         63%
       TRx Volume

                                                                                                                              78%

                                                         0.6                                                100%

                                                                                                  1.0
                                                                                   0.9
                                                                     0.9

                                                         0.3
                                                                                                                                              37%
                                                                                                                              22%
                           Jun   Jul   Aug   Sep   Oct
                                                         0.0
                                                                   2018            2019          2020       2018              2019           2020
Source: Symphony Health TRx Quantity
                                                                                                                   Legacy products   New Entrants
Corporate Presentation
                                                                                                                                                    13
V-Go® for optimized insulin delivery to Type 2 diabetes
 patients: clinically relevant reductions in A1c with less insulin

1. Cziraky M, et al. JHEOR 2019;6(2):70-83. 2. Grunberger G, et al. Drugs Real World Outcomes, 2019. 3. Lajara R, et al. Diabetes Therapy. 2015;6(4):531-545. 4. Harrison C, et al. Poster presented at AACE 26th Annual Scientific Meeting, May 2017. 5. Sutton D, et al. Advances in
Therapy. 35(5), 631-643 2018. 6. Sink J, et al Poster Presented at Diabetes Technology Meeting, Nov. 2014. 7. Wu P, et al. Poster presented at AACE 27th Annual Scientific Meeting, May 2018. 8. Omer A, et al. Poster presented at ADA 73rd Scientific Sessions, June 2013. 9. Hundal
R, et al. Poster presented at the Academy of Managed Care Pharmacy, April 2018. 10. Lajara R, et al. Endocr Pract 2016 Jun;22(6):726-35. 11. Mehta S, et al. Abstract published in The Journal of the American Osteopathic Association Nov 2017:117 and poster presented at OMED 12.
Rosenfeld CR, et al. Endocr Pract. 2012;18(5):660-667. 14
Zealand is well positioned for delivering success
             Experienced Field Force                            Established Market Access Team
           § 15 years average diabetes experience              § 20 years average experience with US payers
           § Long-standing presence with diabetes HCPs         § Existing relationships with key national
             through V-Go                                        and regional payers and PBMs through V-Go
           § Mix of live and inside sales resources covering   § Expanded account management footprint across
             >80% of the Glucagon prescribing market             commercial, medicaid, and medicare accounts

             Scalable Patient Services Footprint                COVID Ready Promotional Mix
           § Existing V-Go® Patient Support capabilities &     § Live and virtual customer engagement mix
             personnel                                           across sales, marketing, market access, patient
           § Optimized patient support capability for            support, and medical affairs
             ZEGALOGUE to help address patient and HCP         § Tested and optimized to succeed in COVID and
             needs at launch                                     post-COVID selling environment

Corporate Presentation                                                                                             15
Clinical
programs•
Corporate Presentation Ÿ   16
Clinical project overview

                         Congenital        Post bariatric   Obesity and
                         Hyperinsulinism   hypoglycemia     associated
                                                            metabolic
                                                            diseases

                         Type 1 diabetes   Short bowel
                                           syndrome

Corporate Presentation                                                    17
Congenital
         Hyperinsulinism
      Congenital hyperinsulinism (CHI) is an
        ultra-rare and devastating congenital
      disorder in newborns. It is caused by a
   defect in pancreatic beta cells, resulting in
         insulin overproduction. This leads to
      persistently and dangerously low blood
                 sugar levels (hypoglycemia).

                                                     “Even though he appears to
                                                      be such a normal kid, any
                                                     moment his blood sugar can
                                                      drop to a really dangerous
                                                                 level.”
                   Read more of Crosby’s story at   Julie, mom to Crosby who was born with
              zealandpharma.com/crosbys-story               congenital hyperinsulinism

Corporate Presentation                                                                       18
Congenital Hyperinsulinism (CHI) is an ultra-rare
 but devastating disorder in neonates and children

 A disease that affects 1:30,000 - 1:50,000 births
 •       ~300 newborns are diagnosed every year with genetically
         determined CHI in the U.S. and EU1,2

 Persistent episodes of hypoglycemia
 •       Most common cause of serious episodes of hypoglycemia
         during childhood, due to inappropriate insulin secretion2,3

 Substantial burden of disease
 •       Insufficient response to existing medical treatment3
 •       High risk of seizures and permanent brain injury4
 •       Most severe cases require pancreatic surgery5
 •       Prolonged hospitalization and intolerable burden to patients,
         families, caregivers, and healthcare systems2,6

1   https://www.orpha.net/consor/cgi-bin/ (not including transient cases due to perinatal stress or diabetic mother); 2 Congenital Hyperinsulinism International. Available at: http://congenitalhi.org; 3 De Leon et al. Nat Clin Pract Endocrinol Metab
     2007;3:57-68, Lubchenco and Bard. Pediatrics. 1971 May;47(5):831-8, Hussain et al. Diabetes 2005 54:2946–2951; 3 Thornton PS et al., J Pediatr. 2015;167(2):238-45; ); 4 Meissner T et al., Long-term follow-up of 114 patients with
     congenital hyperinsulinism. Eur J Endocrinol 2003;149:43-510; 5 Yorifuji et al. Pediatrics International 2014;56:467; 6 Eljamel et al. Orphanet Journal of Rare Diseases 2018;13:123

Corporate Presentation                                                                                                                                                                                                                               19
Congenital hyperinsulinism
Zealand has a comprehensive Phase 3 program
to address the unmet need in CHI
Trial 17109 – Completed*                                                       Trial 17103 - Ongoing                                                          Open-label extension study 17106 -
                                                                                                                                                              Ongoing

                                                                                      12 patients, age 7 days-12 months.                                                         Maximum 44 patients,
  32 patients, age 3 months-12 years.
                                                                                      First patients enrolled; phase 3 trial                                                     age 1 month onwards
            Trial completed
                                                                                            readout expected in 2021

     Hypo-prone, maximum therapy,                                                     Newly diagnosed, dependent on IV                                                 Patients from 17109 and 17103
        incl. pancreatic surgery                                                                  glucose                                                              with ongoing positive benefit/risk

              8 weeks of treatment                                                                 25 days of treatment                                                       Allows for long-term data
               (4 weeks follow-up)                                                                 (4 weeks follow-up)

*Dasiglucagon on top of standard of care (SOC) did not significantly reduce the rate of hypoglycemia compared to SOC alone when assessed by intermittent self-measured plasma glucose (primary endpoint). However, hypoglycemia was
reduced by 40–50% when assessed by blinded continuous glucose monitoring (exploratory analysis). Dasiglucagon treatment was assessed to be safe and well tolerated in the study. 31 out of 32 patients have continued into the long-term
extension study
Corporate Presentation                                                                                                                                                                                                                 20
Dasiglucagon in
           Type 1 Diabetes
              Management
The Bihormonal Bionic Pancreas

      A person with type 1 diabetes depends on
      multiple daily insulin injections to maintain
          plasma glucose in the normal ranges.

                                  Read more at
                           zealandpharma.com

  Corporate Presentation                              21
Glycemic data from phase 2 study supports decision to
    move to phase 3 with bihormonal bionic pancreas
              Phase 2 home-use clinical trial testing                                                                    Phase 3 trial initiation expected in H2 2021 based
         the iLet® bionic pancreas using Dasiglucagon1                                                                       on positive EoP2 meeting with the FDA
                                                       Insulin-Only             Bihormonal

        Mean CGM glucose level                           149 mg/dL               139 mg/dL

            Time spent in range
                                                              71%                         79%
              (70-180 mg/dL)

    Mean CGM glucose
The Bihormonal Bionic Pancreas Pivotal Trial (BH BPPT)
 will serve as the Phase 3 trial for use of Dasiglucagon in the
 iLet for adults and children with T1D
                                                                                                                                                                  Primary endpoint
        ADULTS (≥ 18y)

                            Bihormonal with Dasiglucagon (BHBP)                                                                                                   • A1C superiority of BH
           n ~ 350

                            Insulin-Only iLet (IOBP)                                                                                               BHBP              iLet versus IO iLet (26w)

                            Usual Care*                                                                                                                           Secondary endpoints
                                                                                                                                                                  • A1C superiority of BH
                                                                                                                                                                    iLet versus Usual Care
                                                                                         BHBP
                                                                                                                                                                  • Non-inferiority for time in
                                                                                                                                                                    hypoglycemia/hypo
        PEDS (6–17y)

                            Usual Care*
                                                                                                                                                                    events
          n ~ 350

                            Insulin-Only iLet (IOBP)                                                                                               BHBP
                                                                                                                                                                  • Long-term safety and
                            Bihormonal with Dasiglucagon (BHBP)
                                                                                                                                                                    efficacy as measured
                                                                                                                                                                    over 52 weeks
                         WEEKS                                                    26                                                        52               65
*Usual care will be the insulin treatment the patient is on when rendomized to the trial including multiple daily injections and any marketed insulin pump
Corporate Presentation                                                                                                                                                                      23
Type 1 diabetes
Commercial opportunity
Potential glucagon market value of USD 1-3 billion in 2030 depending on bi-hormonal artificial pancreas pump share of the total diabetes pump
market1

Pump adoption expected to                                                                                        Major growth drivers for dual
increase rapidly                                                                                                 hormone pumps
Estimated number of pump users, U.S. only2

     Fully-automated Bi-Hormonal AP pump                                                                                      Increasing number of insulin-treated Type 1 and 2 Diabetes
     Closed loop insulin-only AP pumps                                             >1,000,000                                 patients3
     Other traditional or hybrid insulin pumps
                                                                                                                              Broader patient segment eligible for pump usage

          400,000                                                                                                             Improving technology and pump system integration

            2018                                  2025                                  2030

1Zealand projections based on glucagon WAC price of USD ~10-15/day. 2 Zealand forecast based on ZS Associates analysis, DataMonitor Diabetes Report 2018, ADA, LSI Report 2018, AACE Report 2014, Meddevicetracker, March
2017. Estimated pump users include T1D and T2D insulin-treated patients. Other traditional pump systems include suspend, predictive suspend, and hybrid closed loop pump systems. 3 JDRF.

Corporate Presentation                                                                                                                                                                                                      24
Dasiglucagon adjustable minidose

    Zealand is exploring novel treatment opportunities for mini-
    doses of dasiglucagon
     Mini-doses of dasiglucagon increase blood glucose
     levels from hypoglycemia in people with type 1                          Exercise-induced hypoglycemia in
     diabetes (T1D)1                                                         T1D
                                                                             • In-clinic trials confirmed potential for
                                                                               dasiglucagon
                                                                             • “Free living” Phase 2 study planned for H1
                                                                               2021

                                                                             Post-Bariatric hypoglycemia (PBH)

                                                                             • In-clinic Phase 2 trial confirmed potential for
                                                                               dasiglucagon in treating PBH
                                                                             • Phase 2b outpatient study planned for H1
                                                                               2021

1   Hovelmann et al. Diabetes, Obesity and Metabolism 2019; 21(3): 601-610
Corporate Presentation                                                                                                           25
BI 456906, a long-acting GLP-1-Glu dual agonist is in Phase 2
as a potential novel treatment of T2D, obesity and NASH
                                                                                                                          Boehringer-Ingelheim is
                                                                                                                          progressing the development of
                                                                                                                          Zealand’s dual agonist BI 456906*

                                                                                                                            Phase 1a: SAD trial         COMPLETED
                                                                                                                            Healthy Volunteers

                                                                                                                            Phase 1b: MAD               COMPLETED
                                                                                                                            Obese/OW; 16 weeks

                                                                                                                            Phase 1: PK/safety          COMPLETED
                                                                                                                            Japanese HV                                      Expected
                                                                                                                                                                             completion
                                                                                                                            Phase 2: T2D
                                                                                                                            350 subjects; 16 wks; Glycemic control, BW
                                                                                                                                                                             Q3 2021

                                                                                                                            Phase 2: Obesity                                 Q3 2022
                                                                                                                            350 subjects; 46 weeks

                                                                                                                            Phase 2: NASH                                    Q1 2023
                                                                                                                            240 subjects; 48 weeks

Sanchez-Garrido MA et al. Diabetologia 2017
* Licensed to Boehringer Ingelheim: EUR 345 million outstanding potential development, regulatory and commercial milestones + high single to low double digit % royalties on global sales   26
Short bowel
                           syndrome
                                                     ”My worst fear was to become
            Patients with SBS have undergone         what I am today: a short bowel
         massive intestinal surgery resulting in
      significantly reduced or complete loss of                 patient.”
                             intestinal function
                                                    Marianne, living with short bowel syndrome

                 Read more of Marianne’s story at
            zealandpharma.com/marianne-story

Corporate Presentation                                                                           27
Glepaglutide is our lead candidate for treatment of SBS

      Glepaglutide1 –                                                                                      Phase 2 data with increases in intestinal absorption
      Long-acting stable GLP-2 analog                                                                      following 3 weeks treatment

      • Forms depot at injection site with                                                                  Change in wet weight                                              Clear dose-response
        effective half-life of ~50 hours                                                                    absorption (g/day)2                                               on multiple endpoints2
      • Once- or twice-weekly dosing via a
        simple autoinjector                                                                                                                                                   • Increase in intestinal fluid
                                                                                                                                                                                and energy absorption
                                                                                                                                                                              • Reduction in fecal wet
                                                                                                                                                                                weight output
                                                                                                                                                                              • Increase in urine production
                                                                                                                                                                              • Increase in body weight
                                                                                                                                                                              • Appeared safe and well-
                                                                                                                                                                                tolerated
                                                                                                                                Mean Baseline Wet Weight Absorption (g/day)
                                                                                                                          525                    538                  288

1   IP protection: Compound patent 2026 + 5 years patent term extension - Dosing regime (pending) 2038 - Clinical formulation (pending) 2039
2   Naimi, R., ASPEN 2018 Nutrition Science and Practice Conference (Abstract number 2829969t).
Corporate Presentation                                                                                                                                                                                         28
Glepaglutide – Pivotal Phase 3 trial progressing
 toward results in 2022

  Trial design
 • Double-blind, placebo
   controlled trial in 129 SBS
   patients evaluating safety and
   efficacy of once and twice
   weekly dosing over 24 weeks

   Primary and key
   secondary endpoints
  • Reduction in weekly parenteral
    support (PS volume)
  • >20% reduction in PS volume
  • Reduction in weekly days on PS

Corporate Presentation                              29
Short bowel syndrome
Commercial opportunity
Opportunity to take majority share of future >USD 1.5 billion market with glepaglutide as potential best-in-class long acting GLP-2 analog

Estimated number of treated SBS                                                                                        Major growth drivers for GLP-treatments
patients and market value potential
across major markets
                                                                                                                                   Increasing awareness of rehabilitation options5
The US 1, 2                            EU 1, 3                                Japan 4
            Patients     Value USD               Patients     Value USD                Patients     Value USD
                                                                                                                                   Improving GLP-2 treatment options
    2020   1,000           ~0.4bn      2020      300              ~0.1bn     2020     0                  -

    2030   >4,000           >1.0bn     2030   >2,000              >0.4bn     2030     >1,000             TBD

                                                                                                                                   Improving therapy adherence

RoW
Potential to be determined

12020 patient and value estimate based on Takeda Q2 2020 financial report, Truven Redbook, WAC and 20-25% discount. 2 2025 forecast based on Transparency Market Research; Short Bowel Syndrome Market, 2017. Number of
patients estimated by dividing with U.S. average price. 3 2030 forecast based on Zealand feasibility study 2018 and annual expected growth of 5%. Value based on existing GLP-2 WAC price. 4 No GLP-2 treatment currently approved in
Japan. Patient forecast based on MHLW estimate. Price level to be defined by first GLP-2 introduction. 5 SBS prevalence doubled in one decade due to increased awareness and improved care (Brandt, 2016,
Journal of Parenteral and Enteral Nutrition).
Corporate Presentation                                                                                                                                                                                                                  30
Dapiglutide has potential to treat SBS as well as a
     wider range of gastrointestinal diseases
       Dapiglutide1,2 - Long-acting GLP-1/GLP-2
                 Vehicle                                                                                                    Clinical progress
                 GLP-2 agonist
       dual agonist
                                                                GLP1/GLP-2 dual agonist                                     Phase 1a (SAD)
                 Small intestine - Total surface2 area

                                                         1000
                                                                            p
Pre-clinical pipeline•

Corporate Presentation   32
Pre-clinical pipeline in obesity and other metabolic
diseases are designed for dual pharmacology
Zealand Pharma addresses dual                                    Amylin analog and GIP agonist induce more weight loss in combination
pharmacology from several angles                                 with GLP-1 versus GLP-1 alone in preclinical obesity model
Dual agonist (one molecule – two actions)                         ZP8396, amylin analog alone and in                                                                                             ZP6590, GIP agonist alone and in
• BI456906 – GLP-1/Glucagon receptor-agonist                      combination with GLP-1                                                                                                         combination with GLP-1

                                                                                                                                  Vehicle
                                                                                                                                                                                                                          Vehicle
                                                                                             Start of ZP Amylin                   GLP-1 analogue
                                                                                            analogue treatment                    ZP Amylin analogue                                                                      ZP GIP
                                                                 700                                                                                                                                         4            GLP-1
                                                                                                                                  GLP-1 analogue + ZP Amylin analogue
                                                                                                                                                                                                             2            GLP-1 + ZP GIP
                                                                                                                                                                                                             0
                                                                 650                                                                                                                                         -2

                                                                                                                                                                        Body weight (% change from day 0)
                                                                                                                                                                                                             -4
                                                                                                                                                                                                                                                                                                    ***
                                                                                                                                                                                                             -6
                                                                                                                                                                                                                                                                                                   6%

                                               Body weight (g)
                                                                 600                                                                                                                                         -8

                                                                                                                                                                                                            -10

Co-formulation or loose combo of mono                                                                                                                                                                       -12
                                                                 550
agonists
                                                                                                                                                                                                            -14
                                                                                                                                                                                                                                                                                                     ***
                                                                                                                                                                                                            -16                                                                                    17%

• ZP8396 – Amylin analog                                         500
                                                                                                                                                                                                            -18

                                                                                                                                                                                                            -20
• ZP6590 – GIP receptor-agonist                                             Pre-treatment
                                                                           GLP-1 analogue                                                                                                                   -22                                                                                      ***
                                                                                                                                                                                                                                                                                                   23%
                                                                                                                                                                                                            -24
                                                                 450                                                                                                                                        -26
                                                                       1     4      7       10      13      16    19    22   25     28    31     34                                                               0   2    4   6   8   10   12   14   16   18   20   22   24   26   28   30   32

                                                                                                    Time (Study days)                                                                                                                             Study days

                                                     • ZP8396 allows for co-formulation with other                                                                      • ZP6590 allows for co-formulation with other
                                                       peptides, including GLP-1 and GIP                                                                                  peptides, including amylin and GLP-1
                                                     • Once weekly dosing                                                                                               • Predicted once weekly subcutaneous dosing
                                                     • Phase 1 anticipated in 2021                                                                                      • In IND enabling toxicology studies

Corporate Presentation                                                                                                                                                                                                                                                                                     33
Pre-clinical pipeline for on IBD and other chronic
  inflammatory diseases
    ZP9830, Kv1.3 blocker for T cell                                                    ZP10000, an α4β7 integrin inhibitor                                      Complement C3 peptide inhibitor –
    driven chronic inflammatory                                                         for oral delivery                                                        outlicenced to Alexion
    diseases incl. IBD
  • Blockage of Kv1.3 ion channels on T effector memory                                 • Binding kinetics on par with antibodies
    cells involved in auto-immunity and chronic                                         • Potential for improved tissue penetration
    inflammation
                                                                                        • Formulation for oral administration being optimized
  • Optimized for selectivity, potency and stability
  • In preparation for IND enabling toxicology studies
                       2000                                                       250                                                          200
                                                                                                                                                                 • Novel long-acting peptide inhibitor of complement C3

                                                                                                                              IL-17A [pg/ml]
                                                                                  200
       IFN-g [pg/ml]

                       1500                                        IL-2 [pg/ml]                                                                150

                                                                                  150                                                                            • Attractive target for peptides not addressable by
                       1000                                                                                                                    100                 antibodies
                                                                                  100

                       500                                                                                                                     50
                                                                                  50                                                                             • Lead molecule half-life extended with improved stability
                         0                                                         0                                                            0                  in formulation and excellent binding properties to C3
                              -14   -12      -10         -8                             -14      -12      -10      -8                                -14   -12     -10       -8
                              Compound conc [log M]                                     Compound conc [log M]                         Compound conc [log M]
                                                                                                                                               • USD 610 million potential development, regulatory and
                                                                                                                                                 commercial milestones + high single to low double
                                                                                                                                                 digits % royalties on net sales
  • Concentration-dependent inhibition of pro-inflammatory                              • Oral dosing of ZP10000 reduces colonic lesion &
    cytokine release (incl. IFN-g, IL-2 and IL17A) from                                   inflammation in pre-clinical IBD disease model***
    stimulated human whole blood*
*Data on file. Concentration-dependent effect on pro-inflammatory cytokine release from Thapsigargin stimulated whole blood.
**For lengths, cm; for Myeloperoxidase (MPO), units per gram protein. Inflammation score is a composite of observations and ranges from 0-4. Mean ± SEM
***ZP10000 administered QD at 100 mg/kg in lipid-based vehicle via oral gavage to mice.
 Corporate Presentation                                                                                                                                                                                                 34
Additional company
information

Corporate Presentation   35
Our next generation peptide platform builds on solid
know-how and new innovative technologies

 Computational chemistry

                                         Library starting points

                                                                   Next generation
                                                                   peptide drugs

     Rational design       Molecular display

                                      Formulation technologies

                                                                               36
Strong balance sheet allows for continued investments
  Net Operating Expenses                                                              Cash position1
  DKK 1,092.1 million / USD 166.9 million                                             DKK 1.28 billion / USD 192.2 million
 DKK thousand                                                                         DKK thousand

1,200,000                                                                             1,600,000

                                                                                      1,400,000
1,000,000
                                                                                      1,200,000
 800,000
                                                                                      1,000,000

 600,000                                                                                   800,000

                                                                                           600,000
 400,000
                                                                                           400,000
 200,000
                                                                                           200,000

          0                                                                                       0
                    2016      2017          2018          2019         2020                              2016         2017         2018          2019         2020
       R&D expenses        G&A expenses        Sales & Marketing expenses                         Cash & cash equivalents        Restricted cash        Securities
                                                                                       1   Excludes an additional DKK 749 million gross proceeds secured through directed issue
 DKK/USD exchange rates used: December 31, 2020 = 6.54 and December 31, 2019 = 6.67
                                                                                           in January 2021

 Corporate Presentation                                                                                                                                                 37
Strategic Partnerships

Strategic collaboration for GLP-1/glucagon                                                                                 Strategic collaboration for up to four
dual agonist1                                                                                                              complement pathway targets3

• EUR 345 million outstanding potential development, regulatory                                                            • Novel long-acting peptide inhibitor of C3 identified
  and commercial milestones + high single to low double digit %                                                            • USD 610 million potential development, regulatory and
  royalties on global sales                                                                                                  commercial milestones + high single to low double digits %
• Product candidate for obesity/Type 2 diabetes/non-alcoholic                                                                royalties on net sales
  steatohepatitis (NASH)                                                                                                   • Up to 3 Additional Targets: USD 15 million upfront/target
• Once weekly dosing                                                                                                         development/regulatory milestones similar to lead target,
• Phase 2 initiated2                                                                                                         commercial milestones and royalties at slight reduction
                                                                                                                           • Multiple opportunities for intervention points for novel targeted
                                                                                                                             therapeutics

1Boehringer Ingelheim holds global development and commercial rights. 2 https://clinicaltrials.gov/ct2/show/NCT04153929. 3 Upfront payment of $25 million for the first target and $15 million equity investment at a subscription price of
$18,68 per share.

Corporate Presentation                                                                                                                                                                                                                        38
Global organization

Copenhagen, Denmark
Boston, MA
                          329
                         Highly skilled employees
                            and diverse teams1
Marlborough, MA
New York, NY

                           1   As of December 31, 2020

Corporate Presentation                                   39
Zealand Pharma is facing an exciting 2021

Launch Zegalogue and optimize                                                                    Advance our early pipeline
commercialization                                                                                 Advance pre-clinical drug candidates towards Phase 1 initiation

     Execute launch readiness program for Zegalogue                                               Initiate new pre-clinical projects

     Launch Zegalogue in late June 2021                                                           Develop our next generation peptide platform

     Deliver on net revenue target for Zegalogue

     Deliver on net revenue target for V-GoTM                                                    Maintain a strong financial and organizational
                                                                                                 position
Execute on clinical pipeline                                                                      Secured a total of DKK gross 749.0 million through a direct issue and private placement of
                                                                                                  new shares –January 2021
     Dasiglucagon for dual-hormone artificial pancreas pump: Initiate Phase 3 study
                                                                                                  Ensure disciplined financial management and productive investments
     Dasiglucagon for congenital hyperinsulinism: Deliver second phase III in 2021 and prepare
     NDA/MAA for execution in 2022 –ongoing                                                       Focus company on operational performance and organizational health
     Glepaglutide for short bowel syndrome: Continue patient enrolment in Phase 3 study –
     ongoing
     Dapiglutide for short bowel syndrome: Complete MAD Phase 1 program

Corporate Presentation                                                                                                                                                                     40
Management

                               Finance & Support
                               Matt Dallas
                               Chief Financial Officer
                                                         US Business & Operations

     Emmanuel Dulac                                      Frank Sanders
     Chief Executive Officer
                               Research & Development
                               Adam Steensberg
                               Chief Medical Officer
                                                         Technical Development
                                                         & Operations
                                                         Ivan M. Møller

                               People & Organization
                               Christina S. Bredal
                                                         Business Development
                                                         Marino Garcia

Corporate Presentation                                                              41
You can also read